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Introduction: Sleep apnea-hypopnea syndrome (SAHS) is one of the extracardiac reasons of atrial fibrillation (AF),
and the prevalence of AF is high in SAHS-diagnosed patients. Nocturnal hypoxemia is associated with AF, pulmonary
hypertension, and nocturnal death. The rate of AF recurrence is high in untreated SAHS-diagnosed patients after
cardioversion (CV). In this study, we present a patient whose SAHS was diagnosed with an apnea test performed
in the intensive care unit (ICU) and who did not develop recurrent AF after the administration of standard AF
treatment and bi-level positive airway pressure (BiPAP).
Case presentation: A 57-year-old male hypertensive Caucasian patient who was on medical treatment for 1.5
months for non-organic AF was admitted to the ICU because of high-ventricular response AF (170 per minute),
and sinus rhythm was maintained during the CV that was performed two times every second day. The results of
the apnea test performed in the ICU on the same night after the second CV were as follows: apnea-hypopnea
index (AHI) of 71 per hour, minimum peripheral oxygen saturation (SpO2) of 67%, and desaturation period (SpO2 of less
than 90%) of 28 minutes. The patient was discharged with medical treatment and nocturnal BiPAP treatment. The
results of the apnea test performed under BiPAP on the sixth month were as follows: AHI of 1 per hour, desaturation
period of 1 minute, and minimum SpO2 of 87%. No recurrent AF developed in the patient, and his medical treatment
was reduced within 6 months. After gastric bypass surgery on the 12th month, nocturnal hypoxia and AF did not
re-occur. Thus, BiPAP and medical treatments were ended.
Conclusions: SAHS can be diagnosed by performing an apnea test in the ICU. SAHS should be investigated in
patients developing recurrent AF after CV. Recovery of nocturnal hypoxia may increase the success rate of
standard AF treatment.
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Atrial fibrillation (AF) is treated with rhythm and speed
control, thromboembolic protection, direct current, and
pharmacological cardioversion (CV). Sleep apnea-
hypopnea syndrome (SAHS) is one of the extracardiac rea-
sons for AF [1]. AF prevalence is known to be high in
SAHS-diagnosed patients [2, 3]. Nocturnal hypoxemia is
associated with AF, pulmonary hypertension, and nocturnal* Correspondence: drbulentgucyetmez@yahoo.com
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creativecommons.org/publicdomain/zero/1.0/death [4-6]. AF recurrence has been reported to be high
(82%) in untreated SAHS-diagnosed patients after CV [7].
In our case, the patient was admitted to the intensive
care unit (ICU) because of high-ventricular response
AF. After CV, SAHS was diagnosed and no recurrent
AF was detected after nocturnal bi-level positive airway
pressure (BiPAP) treatment administered together with
medical treatment.
Case presentation
A 57-year-old male hypertensive Caucasian patient on
medical treatment for 1.5 months for non-organic-related
AF was hospitalized in the ICU because of high-
ventricular response AF (170 per minute). Biphasic CVss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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treatment, and sinus rhythm was maintained. The patient
had high-ventricular response AF (160 per minute) again
after 2 days, biphasic CV with 200J was conducted again,
and sinus rhythm was maintained. An apnea test (AT)
was performed on the same night because frequent apneas
were observed during sedation, and his body mass index
(BMI) was 40.9kg/m2. The results were as follows:
apnea-hypopnea index (AHI) of 71 per hour, desatur-
ation period of 28 minutes, and minimum peripheral
oxygen saturation (SpO2) of 68 %. The patient was dis-
charged with nocturnal BiPAP—expiratory positive air-
way pressure of 8cm H2O and inspiratory positive airway
pressure of 14cm H2O—and medical treatment. The pa-
tient was in sinus rhythm at the 1-month follow-up; thus,
medication doses were decreased, AT was performed under
BiPAP at the 6-month follow-up, and the results were as
follows: AHI of 1 per hour, desaturation period of 1 minute,
and minimum SpO2 of 87 %. The patient did not have AF
within these 6 months. At the 12th month, the patient de-
cided to undergo gastric bypass surgery. Up to the time
of surgery, nocturnal BiPAP and medical treatment were
continued. Within 6 months after the medical surgery, the
patient lost 40kg and only medical treatment was contin-
ued. In the AT conducted in the 18th month (via spontan-
eous breathing), results in the range of AHI of 5 per hour,
apnea index of 1 per hour, and minimum SpO2 of 93 %
were observed; hence, bisoprolol fumarate was ended
(Fig. 1).Fig. 1 The effects of sleep apnea-hypopnea syndrome treatment on atrial
AI, apnea index; BiPAP, bi-level positive airway pressure; BMI, body mass ind
ESS, Epworth sleepiness scale; HR, heart rate; IPAP, inspiratory positive airwaDiscussion
Age, obesity, male gender, hypertension, coronary disease,
and congestive heart failure are the common risk factors
for both AF and SAHS [8]. And nocturnal hypoxia is
known to increase the rate of AF prevalence [2, 3, 6, 7].
Recurrent AF developed despite the medical treatment
and CV in the patient who had a risk of AF because of
obesity and hypertension. Thus, the patient underwent an
AT in the ICU in order to investigate SAHS. An AT can
easily be applied under ICU conditions and is an af-
fordable method through which AHI, less-than-90 %
desaturation period, minimum SpO2, and minimum
and maximum heart rate can be recorded [9]. Severe
SAHS and nocturnal hypoxia were diagnosed in the pa-
tient, who underwent an AT on the same night after
the second CV. Thus, the administration of nocturnal
BiPAP treatment was decided in addition to the stand-
ard AF treatment. Kanagala et al. showed that the rate
of AF recurrence was 82 % 1 year after CV in the un-
treated SAHS-diagnosed patients but regressed to 42 %
after the treatment of SAHS [7]. Besides, in the present
study, AF recurrence was associated with the desaturation
period that was below 90 %. In the present study, it is re-
markable that no AF recurrence developed during the 6
months through which nocturnal BiPAP treatment was
administered and the medical treatment was reduced. In
the AT performed under nocturnal BiPAP treatment at
the sixth month, an improvement was observed in AHI,
minimum SpO2, and less-than-90 % desaturation period.fibrillation treatment. AH, apnea index; AHI, apnea-hypopnea index;
ex; CV, cardioversion; EPAP, expiratory positive airway pressure;
y pressure; SpO2, peripheral oxygen saturation
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tient develop no recurrent AF but also medical treatment
could be reduced and the patient’s quality of life could be
increased as the Epworth sleepiness scale regressed from
17 to 7. Besides, we can say that decreased BMI could be
the main reason for increased quality of life because
BiPAP and medical treatment could be ended after the
gastric bypass surgery.
Apnea is known to cause a sudden decline in the in-
trathoracic pressure, an increase in the left ventricular
transmural pressure, vasoconstriction, and sympathetic
hyperactivity due to arousal [10]. As a result, diastolic
dysfunction, intrathoracic pressure changes, severe hyp-
oxemia, and increased adrenergic state cause fibrosis,
distention, structural, and electrical atrial remodeling
formation [11-13]. The treatment of sleep apnea prevents
intrathoracic pressure fluctuations and autonomic dys-
function and helps to recover atrial myocardium, diastolic
ventricular functions, pro-inflammatory state, and oxida-
tive stress [10, 11, 13-15].
We are of the opinion that the relationship between
the nocturnal hypoxia and AF should be evaluated through
tissue oxygen delivery (DO2). The results acquired by
Kanagala et al. indicate the importance of DO2 in the noc-
turnal hypoxia-AF relationship. DO2 is calculated by multi-
plying the cardiac index (CI) by arterial oxygen content
(CaO2) [16]. Myocardial tissue uses NADH for the produc-
tion of mitochondrial energy [17]. Hypoxia causes a de-
crease in DO2, which enables oxidative phosphorylation
to endure and results in blocking the electron transport
chain and NADH production [18]. Although a recovery
is obtained in CI with the standard treatment of AF, un-
treated nocturnal hypoxia indicates persistence in an in-
sufficient DO2 state in the myocardium cell. This might
explain recurrent AF despite standard treatment. The re-
covery of nocturnal hypoxia together with standard AF
treatment may increase the efficiency of AF treatment by
improving CaO2 and consequently DO2. It may even help
to reduce the medical treatment as in our case. Thus, the
investigation of nocturnal hypoxia together with standard
treatment of AF and simultaneous treatment may increase
the success rate of the treatment.
Conclusions
AF is a clinical status that is life-threatening and hence
its treatment is obligatory. Administration of AF treat-
ment without treating nocturnal hypoxia would reduce
the success of the treatment. Nocturnal BiPAP treatment
may increase the success of AF treatment by reducing
nocturnal hypoxia and DO2. Besides, increased BMI can
be the main reason for SAHS, nocturnal hypoxia, and AF.
That is why, before gastric surgery, nocturnal BiPAP treat-
ment can also be used for safe preoperative preparation.Consent
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